The latest update is out from Sun Pharmaceutical Industries Limited ( (IN:SUNPHARMA) ).
Sun Pharmaceutical Industries Limited announced that the U.S. Court of Appeals for the Federal Circuit has vacated a preliminary injunction, allowing the company to proceed with the launch of LEQSELVI™ (deuruxolitinib) in the United States. This development is a positive step for Sun Pharma as it removes legal barriers to the product’s market entry, potentially enhancing the company’s competitive position and growth prospects in the U.S. market.
More about Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of generic and specialty medicines. The company is a significant player in the global pharmaceutical market, offering a wide range of products across various therapeutic segments.
YTD Price Performance: -10.10%
Average Trading Volume: 60,308
Current Market Cap: 4002.8B INR
See more data about SUNPHARMA stock on TipRanks’ Stock Analysis page.